Cash & Equivalents
Vertex Pharmaceuticals Cash & Equivalents increased by 2.8% to $5.08B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 11.3%, from $4.57B to $5.08B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -3.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.40B | $2.70B | $6.80B | $3.20B | $3.50B | $3.50B | $10.50B | $2.10B | $4.20B | $5.50B | $10.37B | $9.17B | $4.59B | $5.25B | $4.57B | $4.69B | $4.98B | $4.95B | $5.08B |
| QoQ Change | — | +12.5% | +151.7% | -52.9% | +9.4% | +0.0% | +200.1% | -80.0% | +100.0% | +31.0% | +88.5% | -11.6% | -49.9% | +14.3% | -12.9% | +2.5% | +6.3% | -0.7% | +2.8% |
| YoY Change | — | — | — | — | +45.8% | +29.6% | +54.6% | -34.4% | +20.0% | +57.1% | -1.3% | +336.6% | +9.3% | -4.6% | -55.9% | -48.9% | +8.5% | -5.7% | +11.3% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's cash & equivalents?
- Vertex Pharmaceuticals (VRTX) reported cash & equivalents of $5.08B in Q4 2025.
- How has Vertex Pharmaceuticals's cash & equivalents changed year-over-year?
- Vertex Pharmaceuticals's cash & equivalents increased by 11.3% year-over-year, from $4.57B to $5.08B.
- What is the long-term trend for Vertex Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's cash & equivalents has grown at a -3.2% compound annual growth rate (CAGR), from $5.99B to $5.08B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.